TANTALUM NANOCOMPOSITE AND PREPARATION METHOD AND APPLICATION THEREOF, LYMPH TRACER AND RADIOSENSITIZER

Abstract

The invention relates to a tantalum nanocomposite and a preparation method and application thereof, lymph tracer and radiosensitizer. The tantalum nanocomposite provided in the invention includes tantalum nanoparticle and bio-surfactant acting on the tantalum nanoparticle. The tantalum nanocomposite provided in the invention has good biosafety and can improve the effect of radiation therapy as a radiosensitizer.

Claims

1. A tantalum nanocomposite comprising a tantalum nanoparticle and a bio-surfactant coating the surface of the tantalum nanoparticle.

2. The tantalum nanocomposite according to claim 1, wherein the bio-surfactant comprises a polymer surfactant.

3. The tantalum nanocomposite according to claim 2, wherein the polymer surfactant comprises a polyvinyl pyrrolidone, a tween 20, a polyactic acid and one or more of chitosan.

4. The tantalum nanocomposite according to claim 3, wherein the mass average molar mass of the polyvinyl pyrrolidone, the polylactic acid and the chitosan is 58,000, 60,000 and 3,200 respectively.

5. The tantalum nanocomposite according to claim 1, wherein the bio-surfactant comprises a glycolipid, a lipopeptide, a lipoprotein, a fatty acid, a phospholipid and a neutral lipid.

6. The tantalum nanocomposite according to claim 1, wherein the particle diameter of the tantalum nanoparticle is 70-200 nm.

7. The tantalum nanocomposite according to claim 2, wherein the particle diameter of the tantalum nanoparticle is 70-200 nm.

8. The tantalum nanocomposite according to claim 3, wherein the particle diameter of the tantalum nanoparticle is 70-200 nm.

9. The tantalum nanocomposite according to claim 4, wherein the particle diameter of the tantalum nanoparticle is 70-200 nm.

10. The tantalum nanocomposite according to claim 5, wherein the particle diameter of the tantalum nanoparticle is 70-200 nm.

11. The preparation method of tantalum nanocomposite according to claim 1, comprising the following steps: providing a mixture containing the tantalum nanoparticle, the bio-surfactant and water; and performing ball-milling on the mixture to obtain the tantalum nanocomposite.

12. The preparation method of tantalum nanocomposite according to claim 2, comprising the following steps: providing a mixture containing the tantalum nanoparticle, the bio-surfactant and water; and performing ball-milling on the mixture to obtain the tantalum nanocomposite.

13. The preparation method of tantalum nanocomposite according to claim 3, comprising the following steps: providing a mixture containing the tantalum nanoparticle, the bio-surfactant and water; and performing ball-milling on the mixture to obtain the tantalum nanocomposite.

14. The preparation method of tantalum nanocomposite according to claim 4, comprising the following steps: providing a mixture containing the tantalum nanoparticle, the bio-surfactant and water; and performing ball-milling on the mixture to obtain the tantalum nanocomposite.

15. The preparation method according to claim 11, wherein the concentration of the bio-surfactant in water is 0.2-1 g/mL; and/or, the mass ratio of the sum of the mass of the bio-surfactant and the water to the tantalum nanoparticle is 1:1-5:1.

16. The preparation method according to claim 11, wherein the providing a mixture is: dissolving the bio-surfactant into water to obtain a bio-surfactant aqueous solution; and mixing the bio-surfactant aqueous solution with the tantalum nanoparticle.

17. The preparation method according to claim 11, wherein the rotational speed of the ball-milling is 100-300 rpm and the time duration is 1-3 h.

18. The preparation method according to claim 17, further comprising, centrifuging the mixture after performing the ball-milling.

19. The preparation method according to claim 18, wherein the rotational speed of the centrifugation is 12,000 rpm and the time duration is 10 min.

20. The using method of tantalum nanocomposite in lymphatic tracing and/or radio sensitization according to claim 1; and the tantalum nanocomposite is used as a lymph tracer and/or a radiosensitizer.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0024] The attached drawings are only used to show the embodiments, not to limit the invention. Wherein:

[0025] FIG. 1 is a physical image of the tantalum nanocomposite dispersion solution of Example 1;

[0026] FIG. 2 is an image of the tantalum nanocomposite of Example 1 under a transmission electron microscope;

[0027] FIG. 3 is an X-ray diffraction spectrum of the tantalum nanocomposite of Example 1;

[0028] FIG. 4 is a degradation rate diagram of rhodamine B by the tantalum nanocomposite obtained from Example 1-4;

[0029] FIG. 5a is a cell cloning image of contrast group 1 in Example 1;

[0030] FIG. 5b is a cell cloning image of example group 1-1 in Example 1;

[0031] FIG. 5c is a cell cloning image of contrast group 2 in Example 1;

[0032] FIG. 5d is a cell cloning image of example group 1-2 in Example 1;

[0033] FIG. 6a is an image for lymph node of the foot pads of mice before injecting tantalum nanocomposite dispersion in Example 1:

[0034] FIG. 6b is an image for lymph node of the foot pads of mice after injecting tantalum nanocomposite dispersion in Example 1.

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0035] The preferable embodiments of the invention are described specifically below, wherein the drawings are the part of the invention and are used to state the principle of the invention combined with the embodiments of the invention, not to limit the scope of the invention.

[0036] A tantalum nanocomposite or tantalum nanomaterial is provided in an embodiment of the invention, including a tantalum nanoparticle and a bio-surfactant acting on the tantalum nanoparticle.

[0037] In the tantalum nanocomposite of an embodiment of the invention, on one hand, tantalum has good bio-compatibility and higher high-energy ray energy deposition capacity, and can be used as radiosensitizer to improve biosafety and effects of radiation therapy; specifically, after tantalum nanocomposite is added to radiation therapy, the same doses of X-ray cause more cells damage, which shows the enhanced effect.

[0038] On the other hand, bio-surfactant is used to modify tantalum nanoparticle and coated on the surface of tantalum nanoparticle, improving the dispersiveness of tantalum nanocomposite in water and is beneficial to the use of tantalum nanocomposite as radiosensitizer.

[0039] In an embodiment, the particle diameter of the tantalum nanoparticle can be 70-200 nm, such as: 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 180 nm, 200 nm, and etc.

[0040] In an embodiment, the bio-surfactant may be a degradable polymer, and has the advantages of non-toxic, biodegradable, ecological safety and high surface activity. The bio-surfactant has many different kinds, specifically, including glycolipid, lipopeptide and lipoprotein, fatty acid and phospholipid and neutral lipid and polymer surfactant.

[0041] In an embodiment, the bio-surfactant has good bio-compatibility and may be polymer surfactant, such as polyvinyl pyrrolidone, tween 20, polyactic acid and one or more of chitosan.

[0042] In an embodiment, the mass average molar mass of the polyvinyl pyrrolidone may be 58,000.

[0043] The tantalum nanocomposite in an embodiment of the invention can be prepared through physisorption.

[0044] An embodiment of the invention further provides a preparation method of the tantalum nanocomposite, including the following steps: [0045] mixing the bio-surfactant with water to obtain a first mixture; [0046] mixing the tantalum nanoparticle (tantalum powder) with the first mixture to obtain a second mixture, which is processed through ball-milling to enable bio-surfactant to be adsorbed on the surface of tantalum nanoparticle, whereby a tantalum nanocomposite composed of bio-surfactant and tantalum nanoparticle is formed; and [0047] centrifuging the above system containing tantalum nanocomposite to remove the free bio-surfactant and obtain the tantalum nanocomposite.

[0048] In an embodiment, the water used to prepare tantalum nanocomposite may be ultrapure water.

[0049] In an embodiment, the first mixture may be aqueous solution of polyvinyl pyrrolidone at a concentration of 0.2-1 g/mL, such as 0.5 g/mL, 0.6 g/mL, 0.8 g/mL and 1 g/mL.

[0050] In an embodiment, the mass ratio of the tantalum powder and the first mixture (e.g. aqueous solution of polyvinyl pyrrolidone) is 1:1-1:5, such as 1:1, 1:2, 1:3, 1:4 and 1:5.

[0051] In an embodiment, the rotational speed of the ball-milling may be 100 rpm-300 rpm, such as 100 rpm, 150 rpm, 200 rpm, 250 rpm and 300 rpm; the time duration of the ball-milling may be 1-3 h, such as 1.5 h, 2 h, 2.5 h and 3 h.

[0052] In an embodiment, the rotational speed of centrifugation may be 12,000 rpm and the time duration may be 10 min.

[0053] An embodiment of the invention further provides a lymph tracer, including the tantalum nanocomposite above.

[0054] An embodiment of the invention further provides a radiosensitizer, including the tantalum nanocomposite above.

[0055] The tantalum nanocomposite in the embodiment of the invention can enhance the X-ray energy deposition and effectively enhance the production of free radicals and can be used as a radiosensitizer.

[0056] The tantalum nanocomposite in the embodiment of the invention has lymphatic staining tracing properties and can be used as a lymph tracer. Specifically, when using, tantalum nanocomposite can be dispersed into water to form dispersion solution and to be injected into a living organism (e.g. the human body) directly. After the injection, the liquid containing tantalum nanocomposite flows towards and stains the lymph node, whereby the lymph node can be traced and the lymph node can be removed easily, which can be used in lymph node removal surgery.

[0057] The tantalum nanocomposite of the embodiment of the invention has good biosafety and can be used as lymph tracer and radiosensitizer at the same time, the integration of the lymphatic tracing and radiosensitization can be achieved, which has a broad application prospect in the fields such as nanomedicine and tumor inhibition.

[0058] Further description of the preparation and application of tantalum nanocomposite in an embodiment of the invention is stated in combination with the attached drawings and specific examples in the following. Wherein, the raw materials used in the example can be purchased at market. The tantalum powder used is purchased from Xuzhou Jie Innovative Materials Technology Co., Ltd. The average particle diameter is 70 nm and the mass average molar mass of polyvinyl pyrrolidone, polylactic acid and chitosan is 58,000, 60,000 and 3.200 respectively.

Example 1

[0059] The Preparation of Tantalum Nanocomposite

[0060] (1) Dissolving the polyvinyl pyrrolidone in the ultrapure water to obtain an aqueous solution of polyvinyl pyrrolidone at a concentration of 1 g/mL.

[0061] (2) Mixing the tantalum powder with the aqueous solution of polyvinyl pyrrolidone obtained in the step (1) with a mass ratio of 1:5. Performing ball-milling on the obtained mixture, and the rotational speed of the ball-milling is 300 rpm and the time duration is 3 h.

[0062] (3) Centrifuging the mixed liquor after performing ball-milling, and the rotational speed of centrifugation is 12.000 rpm and the time duration is 10 min. Dispersing the centrifugal products into the ultrapure water to obtain the dispersion liquid of tantalum nanomaterial (tantalum nanocomposite) modified by the polyvinyl pyrrolidone.

[0063] FIG. 1 is the image of the dispersion of raw tantalum powder in water and normal saline before and after modifying by polyvinyl pyrrolidone. It can be seen from FIG. 1, the dispersiveness in water of the tantalum nanocomposite is much better than that of tantalum nanoparticle, which fully indicates that in the prepared tantalum nanocomposite, the polyvinyl pyrrolidone acts on the surface of the tantalum nanoparticle, thereby improving the dispersiveness of the tantalum nanoparticle.

[0064] The Transmission Electron Microscopy Characterization on Tantalum Nanocomposite

[0065] Performing transmission electron microscopy characterization on the obtained tantalum nanocomposite above, the images obtained from electron microscope are shown in FIG. 2. It can be seen from FIG. 2, the particle diameter of the nanoparticle of the tantalum nanocomposite is about 70 nm, which indicates the modification by polyvinyl pyrrolidone has no substantial impact on the size of the tantalum nanoparticle.

[0066] The X-Ray Diffraction Characterization on Tantalum Nanocomposite

[0067] Performing X-ray diffraction characterization on the obtained tantalum nanocomposite above, and the resulting spectrum is shown in FIG. 3. It can be seen from FIG. 3, compared with the standard JCPDS spectrum, there is no other miscellaneous peaks in Example 1, which indicates the tantalum powder used is the tantalum nanomaterial with very high purity and almost has no other impurities.

[0068] The Characterization on Free Radical Generating Capacity of Tantalum Nanocomposite

[0069] Rhodamine B is a typical model to study the free radical generating in vitro through degradation and has a characteristic peak in the position of 554 nm. When rhodamine B reacts with the free radical, the absorption value of the characteristic peak is reduced, through which, the effect of the free radical generating can be evaluated. The capacity of the tantalum nanocomposite to generate free radicals is evaluated based on the principle in the following.

[0070] Contrast group: irradiating the rhodamine B solution at a concentration of 5 μg/mL for 10 min through an X-ray tube (50 kV, 75 μA).

[0071] Example groups 1-4: irradiating the solution containing 5 μg/mL rhodamine B and 250 μg/mL tantalum nanocomposite obtained in Examples 1-4 for 10 min through an X-ray tube (50 kV, 75 μA) respectively.

[0072] FIG. 4 shows the absorbance of the above irradiation, and it can be seen that the absorbance of the contrast group is close to 0.8, and the absorbance of example groups 1-4 is about 0.5. The result shows that after adding the tantalum nanocomposite, the absorption value of the characteristic peak of rhodamine B is reduced, which further indicates the tantalum nanocomposite has good free radical generating capacity under the X ray excitation.

[0073] Determination on Radiosensitization Capacity of Tantalum Nanocomposite

[0074] Cell clone is a method to determine cell proliferation ability, the effect of the radiosensitization of the tantalum nanocomposite is stated through evaluating the effect of different groups on cell cloning experiments.

[0075] Culturing the breast cancer tumor cells in six-well plate with 1,000 cells for each well, replacing the complete medium solution into the six-well plate after 24 h, and fixing with paraformaldehyde and staining with Giemsa after 7 days; the system obtained is named as contrast group 1, and the image is shown in FIG. 5a.

[0076] Culturing the breast cancer tumor cells in a six-well plate with 1,000 cells for each well, replacing the complete culture medium solution prepared above at a concentration of 250 μg/mL of the tantalum nanocomposite modified by the polyvinyl pyrrolidone into the six-well plate after 24 h and fixing with paraformaldehyde and staining with Giemsa after 7 days; the system obtained is named as example group 1-1, and the image is shown in FIG. 5b.

[0077] Culturing the breast cancer tumor cells in a six-well plate with 1,000 cells for each well, replacing the complete medium solution into the six-well plate and irradiating with 6 Gy X-ray after 24 h, and fixing with paraformaldehyde and staining with Giemsa; the system obtained is named as contrast group 2, and the image is shown in FIG. 5c.

[0078] Culturing the breast cancer tumor cells in a six-well plate with 1,000 cells for each well, replacing the complete culture medium solution prepared above at a concentration of 250 μg/mL of the tantalum nanocomposite modified by the polyvinyl pyrrolidone into the six-well plate and irradiating with 6 Gy X-ray after 24 h, and fixing with paraformaldehyde and staining with Giemsa after 7 days; the system obtained is named as example group 1-2, and the image is shown in FIG. 5d.

[0079] In can be seen from FIGS. 5a to 5d, both contrast group 1 (FIG. 5a) and example group 1-1 (FIG. 5b) without X-ray irradiation have more cell clones and fewer cell clones in contrast group 2 with X-ray irradiation, while example groups 1-2 containing tantalum nanocomposite are able to form fewer cell clones under X-ray (6 Gy) irradiation than the group (contrast group 2) with only X-ray irradiation, which shows that tantalum nanocomposite has good ability of radiosensitization.

[0080] Determination on Lymphatic Tracing Ability of Tantalum Nanocomposite

[0081] Injecting the above aqueous dispersion (75 mg/mL, 75 μL) of the tantalum nanocomposite into the foot pads of BALB/c male mice, observing the staining of the lymph node after 90 minutes and killing the mice for taking out the lymph node to be observed. FIG. 6a is the image of lymph node of the mice before injecting aqueous dispersion of tantalum nanocomposite, and FIG. 6b is the image after injection; the color change of the area shown by the arrow in FIG. 6b before and after injection shows that both popliteal lymph node and nodi lymphatici iliaci have a better staining effect, which further shows that tantalum nanocomposite has the ability of lymphatic staining and tracing.

Example 2

[0082] The same raw materials and steps with Example 1 are adopted in the example, the only difference is that: the bio-surfactant adopted is tween 20. The result of the characterization on free radical generating capacity of the tantalum nanocomposite is shown in FIG. 4.

Example 3

[0083] The same raw materials and steps with Example 1 are adopted in the example, the only difference is that: the bio-surfactant adopted is polylactic acid. The result of the characterization on free radical generating capacity of the tantalum nanocomposite is shown in FIG. 4.

Example 4

[0084] The same raw materials and steps with Example 1 are adopted in the example, the only difference is that: the bio-surfactant adopted is chitosan. The result of the characterization on free radical generating capacity of the tantalum nanocomposite is shown in FIG. 4.

[0085] The above results fully indicate that the tantalum nanocomposite in the examples of the invention can enhance the generation of free radicals in tumor area under X-ray irradiation to improve the effect of radiation therapy. In addition, the tantalum nanocomposite in the examples of the invention can stain and trace the lymph node, which helps to remove the lymph node.

[0086] The above mentioned are only the better embodiments of the invention, not the limitation of the invention. Within the technical scope disclosed by the invention, any modifications or replacements that can easily be thought of by any skilled familiar with the technical field shall be covered by the protection scope of the invention.